December 14, 2023
July 27, 2023
July 27, 2023
March 1, 2023
Duarte, Calif., March 1, 2023 – CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, […]
November 10, 2022
Monrovia, Calif., November 10, 2022, CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today […]
September 7, 2022
Monrovia, Calif., September 7, 2022, CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, […]
July 28, 2022
Los Angeles and Monrovia, Calif., July 28, 2022, CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based […]
April 11, 2022
MONROVIA, Calif, April 11, 2022–CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of natural killer (NK) cell-based cancer therapies, announced new preclinical data supporting […]
April 7, 2022
MONROVIA, Calif., April 07, 2022 –(BUSINESS WIRE)–CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, […]